| NCT06210945 | Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis | SUSPENDED | PHASE2 | 2024-09 | 2026-12 | 2026-06 |
| NCT05824156 | CM-101 in NASH Patients - The SPLASH Study | COMPLETED | PHASE2 | 2021-02-24 | 2022-08-25 | 2022-08-15 |
| NCT04595825 | CM-101 in PSC Patients -The SPRING Study | ACTIVE_NOT_RECRUITING | PHASE2 | 2020-10-01 | 2025-09 | 2024-09 |
| NCT06037577 | Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects | COMPLETED | PHASE1 | 2019-03-05 | 2019-05-05 | 2019-05-05 |
| NCT06044467 | The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects | COMPLETED | PHASE1 | 2018-12-11 | 2020-04-27 | 2020-04-27 |
| NCT06025851 | Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects | COMPLETED | PHASE1 | 2017-07-24 | 2018-02-18 | 2018-02-18 |